Pharma's Almanac

First-in-Class Drugs

1 / 1

First-in-Class Drugs

Breaking New Ground: 30 Years of First-in-Class Drug Innovation

Cynthia A. Challener, Ph.D.

Pharma's Almanac

PAO-25-30-27Apr 09, 2025

FDA New Drug Approvals

Many First-in-Class Drugs Approved by FDA in 2022, but Overall Approval Numbers Down

Cynthia A. Challener, Ph.D.

Pharma's Almanac

PAO-03-23-NI-03Mar 07, 2023

Drug Development

Novartis Licenses First-in-Class Heart Disease Drug

Emilie Branch

Pharma's Almanac

PAO-M03-19-NI-008Mar 05, 2019

FDA Analysis

FDA Analysis Shows Reduced Competition for First-in-Class Drugs

Cynthia A. Challener, Ph.D.

Pharma's Almanac

PAO-M08-18-NI-002Jul 31, 2018

1 / 1

Mobile Navigation

Subscribe for the Newsletter

First-in-Class Drugs

First-in-Class Drugs

Breaking New Ground: 30 Years of First-in-Class Drug Innovation

Cynthia A. Challener, Ph.D.

Pharma's Almanac

FDA New Drug Approvals

Many First-in-Class Drugs Approved by FDA in 2022, but Overall Approval Numbers Down

Cynthia A. Challener, Ph.D.

Pharma's Almanac

Drug Development

Novartis Licenses First-in-Class Heart Disease Drug

Emilie Branch

Pharma's Almanac

FDA Analysis

FDA Analysis Shows Reduced Competition for First-in-Class Drugs

Cynthia A. Challener, Ph.D.

Pharma's Almanac

First-in-Class Drugs

Breaking New Ground: 30 Years of First-in-Class Drug Innovation

Cynthia A. Challener, Ph.D.

Pharma's Almanac

FDA New Drug Approvals

Many First-in-Class Drugs Approved by FDA in 2022, but Overall Approval Numbers Down

Cynthia A. Challener, Ph.D.

Pharma's Almanac

Drug Development

Novartis Licenses First-in-Class Heart Disease Drug

Emilie Branch

Pharma's Almanac

FDA Analysis

FDA Analysis Shows Reduced Competition for First-in-Class Drugs

Cynthia A. Challener, Ph.D.

Pharma's Almanac